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0.5, N = 2384), moderate (0.5 < APRI&LE;1.5, =″/″ and=″″
(apri=″″ severe=″″ n=″377),″>1.5, N = 116). Per patient use and
costs of HCV-related medical services and prescriptions were
assessed over 12 months post-diagnosis. RESULTS: More than
23% of patients with severe HCV had a disease-related hospital-
ization compared to 12%and 16%ofmild andmoderate patients,
respectively (both P < 0.05). Hospitalization costs were nearly
2.5 times higher in moderate patients ($3480) and approximately
4.7 times higher in severe patients ($6872) compared to thosewith
mild disease ($1448; both P < 0.01). Severe patients also had a
signiﬁcantly (P < 0.01) higher mean number of hospital days (7.9)
compared to moderate (6.7 days) and mild patients (4.1 days).
There were no signiﬁcant differences in encounters and costs for
physician ofﬁce and emergency department visits. Severe patients
had slightly lower (but insigniﬁcant) HCV-related pharmacy costs
compared to mild and moderate patients. After controlling for
demographics and comorbidities in a multivariate analysis, mild
patients incurred $4708 less (P < 0.01) in total HCV-related costs
compared to severe patients. CONCLUSIONS: Patients with
moderate and severe HCV incur nearly twice the medical costs of
patients with mild disease, due primarily to increased hospitaliza-
tions. There was no signiﬁcant difference in ambulatory resource
use and costs between moderate and severe patients.
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OBJECTIVES: Early diagnosis of ﬁbromyalgia and its manage-
ment represent a public health issue for the health authorities
who allocate resources. Career interruptions and absences from
work consume a signiﬁcant share of these resources.The aim was
to describe the characteristics of subjects who reported career
interruptions or sick leaves in UK, METHODS: Four question-
naires, the LFESSQ (London Fibromyalgia Epidemiology Study
Screening Questionnaire), the CES-D (Center for Epidemiologic
Studies Depression Scale), the SQA (Sleep Quality Assessment),
and the FMQ (Fibromyalgia Moldofsky Questionnaire), were
administered to a representative community sample in UK. A
descriptive analysis of career interruptions and sick leaves was
carried out using social and demographic data and symptoms
supplied by the subjects surveyed, RESULTS: 25.1% stated that
they were not working at the time of the survey, with signiﬁcantly
more women (34.3% vs 15.5%), subjects over 50 (50.5% vs
4.9%) and with a low income (58.2% vs 45.9%). Subjects with
pain (LFESSQ positive), a strong presumption of ﬁbromyalgia
syndrome (FMQ > 8), with an unrestorative sleep (SQA >= 14),
a possible depressive symptoms (CES-D > 17) were signiﬁcantly
more frequently inactive. 24.8% had been absent during the last
year (average of 8.6 absence days). Subjects with pain, a strong
presumption of ﬁbromyalgia, an unrestorative sleep, a possible
depressive symptoms were not more frequently absent from
work. The number of absence days increased signiﬁcantly with
the number of concomitant symptoms: 1 day for subjects expe-
riencing pain, 1.8 for subjects with a sleep disorder, 3.3 for pain
and fatigue, 3.8 for pain and probable depressive symptoms,
reaching 5.1 days for a combination of pain, fatigue and prob-
able depressive symptoms, CONCLUSIONS: Career interrup-
tions were signiﬁcantly more common in subjects who screened
positive on the LFES-SQ and who had a strong presumption of
ﬁbromyalgia syndrome, whereas absence from work mostly
affected subjects with a sleep disorder.
PODIUM SESSION I: MEDICAL DEVICE
ECONOMIC EVALUATIONS
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OBJECTIVES: To evaluate the long-term clinical and economic
outcomes of treating adults and adolescents with type 1 diabetes
with continuous subcutaneous insulin infusion (CSII) versus mul-
tiple daily injections (MDI) in Poland. METHODS: A validated
model was used to estimate the lifetime impact of CSII-related
improvements in diabetes control on quality-adjusted life-
expectancy (QALE), occurrence of complications, and direct
medical costs in two Polish type 1 diabetes cohorts (Adult—mean
age 37.8 years, duration of diabetes 10.4 years, mean HbA1c
9.40%; adolescent—mean age 14.0 years, duration of diabetes
1.0 year, mean HbA1c 9.40%, no baseline complications). Treat-
ment effects of CSII were deﬁned from a meta-analysis as a
reduction of 0.95% in HbA1c and a decrease in severe hypogly-
cemia (14.8 versus 62 events per 100 patient-years) compared
with MDI. Future costs and beneﬁts were discounted at 5%
annually and projected over the patient’s lifetime. All costs were
evaluated in 2006 Polish Zloty and converted to Euro (€).
RESULTS: CSII was associated with improvements in QALE
(0.35 and 0.46 quality-adjusted life-years [QALYs] for adults and
adolescents, respectively) and fewer diabetes-related complica-
tions versus MDI. Over patient’s lifetime CSII versus MDI for
adults and adolescents was projected to reduce the cost of renal
disease by €865 and €413 and cost of hypoglycaemia by €576
and €3,463, respectively. For adults and adolescents CSII was
projected to cost €9,309 and €19,294 more than MDI over a
patient’s lifetime, respectively. CSII was associated with an incre-
mental cost-effectiveness ratio (ICER) of €20,778 for adults and
€14,968 for adolescents per QALY gained versus MDI. CON-
CLUSIONS: Based on the threshold proposed by the World
Health Organization (4 times the Gross Domestic Product per
capita, approximately €26,000), CSII treatment improves clinical
outcomes and represents a cost-effective treatment option com-
pared with MDI for patients with type 1 diabetes in Poland.
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